The PRoFESS trial results: what went wrong?

Suppr

超能文献

作者信息

Anderson Craig S

机构信息

The George Institute for International Health, PO Box M201, Missenden Road, Camperdown NSW 2050.

出版信息

Int J Stroke. 2008 Aug;3(3):165-6. doi: 10.1111/j.1747-4949.2008.00212.x.

DOI:10.1111/j.1747-4949.2008.00212.x

PMID:18705892

Abstract

摘要

相似文献

The PRoFESS trial results: what went wrong?

Int J Stroke. 2008 Aug;3(3):165-6. doi: 10.1111/j.1747-4949.2008.00212.x.

[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].

MMW Fortschr Med. 2008 May 22;150(21):7.

Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.

Cardiovasc J Afr. 2008 May-Jun;19(3):165.

[ASS plus dipyridamole or clopidogrel after stroke: what is the best secondary prevention?].

MMW Fortschr Med. 2008 May 22;150(21):6-7.

Antiplatelets for stroke prevention: implications of the PRoFESS trial.

Stroke. 2009 May;40(5):1936-7. doi: 10.1161/STROKEAHA.108.537829. Epub 2008 Nov 26.

ProFESS trial: any lessons to learn for future anti-platelet trials?

Int J Stroke. 2009 Dec;4(6):458-60. doi: 10.1111/j.1747-4949.2009.00382.x.

Antiplatelet therapy: a neurology perspective.

Manag Care. 2000 Oct;9(10 Suppl):13-5.

Antiplatelet therapy: a neurology perspective.

Manag Care. 2000 May;9(5 Suppl):15-7.

[Old and new platelet aggregation inhibitors: which to choose for prevention of stroke?].

Rev Med Suisse Romande. 2000 Sep;120(9):697-702.

Antiplatelet agents. European perspective.

Adv Neurol. 2003;92:293-9; discussion 301-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The PRoFESS trial results: what went wrong?

Int J Stroke. 2008 Aug;3(3):165-6. doi: 10.1111/j.1747-4949.2008.00212.x.

[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].

MMW Fortschr Med. 2008 May 22;150(21):7.

Cardiovasc J Afr. 2008 May-Jun;19(3):165.

[ASS plus dipyridamole or clopidogrel after stroke: what is the best secondary prevention?].

MMW Fortschr Med. 2008 May 22;150(21):6-7.

Antiplatelets for stroke prevention: implications of the PRoFESS trial.

Stroke. 2009 May;40(5):1936-7. doi: 10.1161/STROKEAHA.108.537829. Epub 2008 Nov 26.

ProFESS trial: any lessons to learn for future anti-platelet trials?

Int J Stroke. 2009 Dec;4(6):458-60. doi: 10.1111/j.1747-4949.2009.00382.x.

Antiplatelet therapy: a neurology perspective.

Manag Care. 2000 Oct;9(10 Suppl):13-5.

Antiplatelet therapy: a neurology perspective.

Manag Care. 2000 May;9(5 Suppl):15-7.

[Old and new platelet aggregation inhibitors: which to choose for prevention of stroke?].

Rev Med Suisse Romande. 2000 Sep;120(9):697-702.

Antiplatelet agents. European perspective.

Adv Neurol. 2003;92:293-9; discussion 301-5.